FOLH1 and Familial prostate cancer: After many years of preclinical research on PSMA ligands, the breakthrough was achieved in 2011 with the clinical introduction of Glu-NH-CO-NH-Lys(Ahx)-HBED-CC (68Ga-PSMA-11) for PET imaging and 131I–MIP-1095 for radioligand therapy of prostate cancer [6–12].